An observational study in Axial Length, Myopia and Child Development, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Recruiting at 2 sites in China. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Observational
The primary objective of this multi-center, observational study is to establish the reference ranges of axial length in Chinese children and adolescents.
30,000 children aged 3-18 years were examined with cycloplegia to collect their ocular parameters and were all followed up for three years with annual visits.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 150 across 204 observational studies indexed under Myopia.
Browse Myopia studies →Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 66 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Students aged from 3 to 18 years old were recruited from schools to enroll the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To collect the ocular data among myopic children.
To collect the ocular data among non-myopic children.
Axial length
Axial length in millimeter was examined by IOL Master
Time frame: 2023-2026
Axial length elongation
The elongation in millimeter was the difference between two annual visits.
Time frame: 2023-2026
Comparison of visual acuity outcomes obtained by VA charts with different optotypes among children
This outcome measure evaluates differences in uncorrected visual acuity (UCVA) results obtained using HOTV and Tumbling E logMAR charts among children aged 3-15 years.
Time frame: Baseline vision testing at enrollment (single study visit)
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
Of 87 non-industry observational studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's planned 45 months is above that.
Counting every sponsor, half of 96 studies reached it within 24 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center